About Divi’s Laboratories Limited

Divi’s Laboratories Limited, founded in 1990 and headquartered in Hyderabad, is one of the world’s leading manufacturers of active pharmaceutical ingredients (APIs). Its core businesses span Generic APIs, Custom Synthesis for innovator pharma companies, and Nutraceutical ingredients. Divi’s serves customers in over 100 countries, working with 12 of the world’s top 20 pharmaceutical companies.

The company is among the top three global API makers and the largest producer of 10 out of 30 APIs in its portfolio. Its nutraceuticals division manufactures carotenoids and vitamins for dietary supplements, food, beverages, pet food, and feed, with products including Beta Carotene, Astaxanthin, Lycopene, Lutein, and vitamins A, D3, and E Acetate.

Divi’s operates three large manufacturing campuses across Telangana and Andhra Pradesh, supported by three R&D centers and overseas subsidiaries in the USA (New Jersey) and Switzerland (Basel).

Divi’s Laboratories Limited’s Business Segments

• Generic APIs: High-quality APIs across cardiovascular, anti-inflammatory, oncology, and CNS therapies.

• Custom Synthesis: End-to-end solutions for innovator companies, from early clinical to late life-cycle stages.

• Nutraceuticals: Carotenoids and vitamins tailored for supplements and food industries.

Exports accounted for 88% of FY25 revenue, reflecting Divi’s global scale.

Geographic Revenue (FY25 standalone): Europe ₹5,192 crore (56%), North America ₹1,488 crore (16%), Asia ₹1,044 crore (11%), India ₹1,105 crore (12%), Rest of World ₹367 crore (4%).

Divi’s Laboratories Limited’s Key Management

• Dr. Murali K. Divi – Managing Director, leads strategy and operations.

• Dr. Kiran S. Divi – Whole-time Director & CEO, oversees execution.

• N. V. Ramana – Executive Director, supports business operations.

Latest Updates (FY25) on Divi’s Laboratories Limited

• Capacity expansion: Began operations at Unit 3, Kakinada, on Jan 1, 2025, boosting manufacturing footprint.

• Technology: Added infrastructure for peptide synthesis (solid and liquid phase).

• Regulatory: Successfully cleared US FDA inspection at Unit 2.

• Financials: Standalone income ₹9,550 crore; PAT ₹2,209 crore; EPS ₹83.20.

• Capital investment: Deployed ₹1,118 crore into expansion, backward integration, and technology.

• Dividend: Recommended ₹30 per share final dividend (record date July 25, 2025).

• Credit rating: CARE reaffirmed AA+ (Stable).

• Sustainability: Achieved CDP “B” rating, conserved ~34,870 GJ energy, recycled over 1.1 million KL water, and recorded ~38 million safe man-hours.